title: Novel panel of cerebrospinal fluid biomarkers for the prediction of progression to Alzheimer dementia in patients with mild cognitive impairment.
abstract: OBJECTIVE
  To use proteomic analysis of cerebrospinal fluid to discover novel proteins and peptides able to differentiate between patients with stable mild cognitive impairment (MCI) and those who will progress to Alzheimer disease (AD).
  
  
  METHODS
  Baseline cerebrospinal fluid samples from patients with MCI and healthy controls were profiled using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry.
  
  
  METHODS
  Memory disorder clinic.
  
  
  METHODS
  Patients with MCI (n = 113), of whom 56 were cognitively stable and 57 progressed to AD with dementia during a 4- to 6-year follow-up, as well as 28 healthy controls who were followed up for 3 years. Main Outcome Measure During follow-up, 57 patients progressed to AD and 56 patients had stable MCI. Cerebrospinal fluid from these 2 groups of patients was compared using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry.
  
  
  RESULTS
  We identified a panel of 17 potential biomarkers that could distinguish between patients with stable MCI and patients with MCI who progressed to AD. We have positively identified and characterized 5 of the potential biomarkers.
  
  
  CONCLUSIONS
  Proteomic profiling of cerebrospinal fluid provided a novel panel of 17 potential biomarkers for prediction of MCI progression to AD. The 5 identified biomarkers are relevant to the pathogenesis of AD and could help gain an understanding of the molecular pathways in which they may function.
authors.affiliation: Biomarker Discovery Center Facility, Ciphergen Biosystems, Inc., 2100 Copenhagen O, Denmark. asimonsen@ciphergen.com
authors.forename: Anja H
authors.initials: AH
authors.lastname: Simonsen
authors.forename: James
authors.initials: J
authors.lastname: McGuire
authors.forename: Oskar
authors.initials: O
authors.lastname: Hansson
authors.forename: Henrik
authors.initials: H
authors.lastname: Zetterberg
authors.forename: Vladimir N
authors.initials: VN
authors.lastname: Podust
authors.forename: Huw A
authors.initials: HA
authors.lastname: Davies
authors.forename: Gunhild
authors.initials: G
authors.lastname: Waldemar
authors.forename: Lennart
authors.initials: L
authors.lastname: Minthon
authors.forename: Kaj
authors.initials: K
authors.lastname: Blennow
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000134:cerebrospinal fluid* / Q000209:etiology*; D015415:Biomarkers / Q000134:cerebrospinal fluid*; D003072:Cognition Disorders / Q000134:cerebrospinal fluid* / Q000150:complications*; D018450:Disease Progression; D005260:Female; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D011237:Predictive Value of Tests; D040901:Proteomics / Q000379:methods; D018709:Statistics, Nonparametric
chemical_list: D015415:Biomarkers